Teva gets FDA nod for generic TOBI

The FDA approves Teva's (TEVA -0.9%) generic version of the Novartis (NVS -0.2%) CF treatment TOBI.

TEVA expects to launch the product late next month.

TOBI had annual U.S. sales of ~$350M. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs